Search results
Found 22111 matches for
Convalescent plasma has been widely used as a treatment for COVID-19 but to date there has been no convincing evidence of the effect of convalescent plasma on clinical outcomes in patients admitted to hospital with COVID-19. Recruitment to the convalescent plasma arm of the RECOVERY trial has now closed. The preliminary analysis based on 1873 reported deaths among 10,406 randomised patients shows no significant difference in the primary endpoint of 28-day mortality. Recruitment to all other treatment arms – tocilizumab, aspirin, colchicine, and Regeneron’s antibody cocktail – continues as planned.
James Berkley
MBBS MTropMed MRCP MD FRCPCH FMedSci James Berkley - Professor of Paediatric Infectious Diseases
Peter Horby
FRS Peter Horby - Moh Family Foundation Professor of Emerging Infections and Global Health
Brian Angus
BSc, MBChB, DTM&H, FRCP, MD, FFTM Brian Angus - Professor of Practice, Medical Education and Reader in Infectious Diseases
